TOTALL Diabetes Hormone Institute

Recent papers from TOTALL Diabetes Hormone Institute

1. The Varanasi Declaration 2026: an India-specific consensus policy framework for integrated cardiovascular–kidney–metabolic careThe Lancet Regional Health - Southeast Asia · 2026
2. Positioning of Semaglutide among Evolving Guidelines in the Management of Obesity and Related ComorbiditiesInternational Journal of Diabetes and Technology · 2026
3. Research Society for the Study of Diabetes in India (RSSDI) multidisciplinary expert consensus recommendations on role of oral fluid, electrolytes, and energy management in persons with diabetesInternational Journal of Diabetes in Developing Countries · 2025
4. Indian Clinicians’ Perspectives on Utilizing Dapagliflozin-Based Combination Therapy for the Management of Obesity in Patients With Type 2 Diabetes MellitusCureus · 2025
5. Expert Consensus Statement on Simplified Glycemic Care in Patients With Type 2 Diabetes MellitusCureus · 2025
6. Multicenter, Phase 4 Clinical Study from India to Evaluate the Safety and Efficacy of Insulin Glargine 300 U/ml in Insulin-Naïve People with Type 2 Diabetes Uncontrolled on Oral Anti-hyperglycemic Drugs: SAFEGUARD StudyDiabetes Therapy · 2025
7. Two Concerns and A Single Solution in Managing Type 2 Diabetes: A Narrative Review on ImegliminJournal of the Association of Physicians of India · 2025
8. Artificial Intelligence in Healthcare: Current Trends and Future DirectionsCurrent Medical Issues · 2025
9. Responsible Use of Oral Corticosteroids in People with Comorbid Diabetes: An Expert ConsensusJournal of the Association of Physicians of India · 2024
10. A real-world retrospective study of omeprazole– domperidone combination in managing acid peptic disease with PRoton-pump Inhibitors in patients with type 2 DiabEtes mellitus (PRIDE-2)Drugs in Context · 2023
11. Evolution of Guideline Recommendations on Insulin Therapy in Type 2 Diabetes Mellitus Over the Last Two Decades: A Narrative ReviewCurrent Diabetes Reviews · 2023
12. Randomized, double-blind, placebo-controlled trial of ISC 17536, an oral inhibitor of transient receptor potential ankyrin 1, in patients with painful diabetic peripheral neuropathy: impact of preserved small nerve fiber functionPain · 2021
13. Insulinization in T2DM with Basal Analogues During COVID-19 Pandemic: Expert Opinion from an Indian PanelDiabetes Therapy · 2020
14. Best Practices and Tools for Titrating Basal Insulins: Expert Opinion from an Indian Panel via the Modified Delphi Consensus MethodDiabetes Therapy · 2020
15. Liraglutide as add‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trialDiabetes Obesity and Metabolism · 2020
16. Suboptimal glycemic control among subjects with diabetes mellitus in India: a subset analysis of cross-sectional wave-7 (2016) data from the International Diabetes Management Practices Study (IDMPS)Therapeutic Advances in Endocrinology and Metabolism · 2020
17. Diabetes insipidus: The other diabetesIndian Journal of Endocrinology and Metabolism · 2015
18. Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metforminDiabetes Obesity and Metabolism · 2015
19. Evaluation of skin and subcutaneous tissue thickness at insulin injection sites in Indian, insulin naïve, type-2 diabetic adult populationIndian Journal of Endocrinology and Metabolism · 2013
20. Barriers and solutions to diabetes management: An Indian perspectiveSHILAP Revista de lepidopterología · 2013